AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Primary MyelofibrosisHematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationLeukemia, Myeloid, AcuteGraft vs Host DiseaseTransplantation ConditioningLeukemia, MyeloidTransplantation, AutologousHematologic NeoplasmsPeripheral Blood Stem Cell TransplantationLeukemiaRemission InductionTransplantation ChimeraLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTreatment OutcomeStem CellsBone Marrow TransplantationGraft vs Leukemia EffectBusulfanRecurrenceMyeloablative AgonistsVidarabineMyelodysplastic SyndromesTissue DonorsAcute DiseaseGraft vs Tumor EffectCytarabineHematopoietic Stem CellsPrecursor Cell Lymphoblastic Leukemia-LymphomaHistocompatibility TestingGraft SurvivalDisease-Free SurvivalSurvival AnalysisRetrospective StudiesLymphocyte TransfusionSurvival RateNeoplasm, ResidualImmunosuppressive AgentsCombined Modality TherapyMultiple Myelomafms-Like Tyrosine Kinase 3Antineoplastic Combined Chemotherapy ProtocolsSalvage TherapySiblingsWhole-Body IrradiationPrognosisCord Blood Stem Cell TransplantationCytomegalovirus InfectionsMinor Histocompatibility AntigensBone MarrowLymphocyte DepletionAntineoplastic AgentsAntilymphocyte SerumBenzamidesLiver TransplantationFusion Proteins, bcr-ablTime FactorsAntigens, CD34HistocompatibilityVirus ActivationBlast CrisisCytogenetic AnalysisMelphalanLeukemia, Lymphocytic, Chronic, B-CellCyclophosphamidePyrimidinesGene Expression Regulation, LeukemicHepatic Veno-Occlusive DiseaseChimerismFollow-Up StudiesPiperazinesLeukemia, Myeloid, Accelerated PhaseMyeloproliferative DisordersT-LymphocytesHematopoietic Stem Cell MobilizationMesenchymal Stem Cell TransplantationPolycythemia VeraCytomegalovirusAnemia, AplasticHLA AntigensLeukemia, Myelomonocytic, AcuteHematologic DiseasesCell TransplantationJanus Kinase 2Flow CytometryFatal OutcomeThrombocythemia, EssentialBone Marrow CellsCell DifferentiationGranulocyte Colony-Stimulating FactorKidney TransplantationEmbryonic Stem CellsAntibodies, NeoplasmDaunorubicinKaryotypingImmunophenotypingEtoposideImmunocompromised HostIdarubicin
NeoplasmsEssential thrombocythemiaGraft versusAutologous transplantationTransplantMyelodysplastic SyndromesRefractoryBonePolycythemiaRelapse2023MutationsMalignanciesMultiple myelomaSurvivalNeoplasmHematologyLymphomaHSCTIntermediate or high-risk myelofibrosisTransplantsMyelogenous LeukemiaCancersHematologicSecondary acute leukemiaPromyelocytic leukemiaHematopoietic cellsDiagnosisChemotherapyAdultsPlateletsProliferationSplenomegalyChronic myeloid disordersMutationThrombocytopeniaHematopoiesisTherapy for patients with myelofibrosisIncidenceRenal cell carcProgenitorClinical TrialsPeripheral blood stemMPNsTyrosine kinase inhDonorMegakaryoblasticJAK2PrimarySevereHematopoetic stem cellBlast phase
Neoplasms18
Essential thrombocythemia12
Graft versus3
  • Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. (stembook.org)
  • Chronic Graft-Versus-Host Disease, Non-Relapse Mortality and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A CIBMTR Analysis. (stembook.org)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
Autologous transplantation2
Transplant31
  • Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. (mdanderson.org)
  • According to a presentation at SOHO 2023, overall survival was boosted among patients from the QuANTUM-First trial who went to transplant in first remission and were treated with quizartinib for their FLT3-ITD-positive acute myeloid leukemia. (targetedonc.com)
  • Apamistamab (Iomab-B) conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia (AML), according to interim results from the phase 3 SIERRA trial, which were presented virtually at the 2021 Transplant and Cellular Therapies Meetings. (onclive.com)
  • In these patients with relapsed or refractory AML, we observed high rates of allogeneic stem cell transplant with curative intent [in] 88% of patients on the Iomab-B arm, 18% of patients who were randomized to the conventional care arm achieved complete remission and received standard of care allo-transplant, and an overall rate of 79% of allo-transplant in all enrolled patients," Boglarka Gyurkocza, MD, said in a virtual presentation. (onclive.com)
  • Transplant Cell Ther. (stembook.org)
  • Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study. (stembook.org)
  • A Simple Prognostic System in Myelofibrosis Patients Undergoing Allogeneic Stem Cell Transplant: A CIBMTR/EBMT analysis. (stembook.org)
  • Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients. (stembook.org)
  • Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. (stembook.org)
  • Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients. (stembook.org)
  • Hematopoietic stem cell transplant. (mayoclinic.org)
  • http://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. (mayoclinic.org)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
  • The 5-year probability of overall survival (OS) after allogeneic HCT was estimated to be 56% (95% confidence interval[CI], 55%- 57%) for patients receiving a transplant while in CR, and 22% (95% CI, 21%-23%) for those who were experiencing active disease. (apbmt.org)
  • This group etic stem cell transplant (HSCT) (8 allogeneic) and in 15 of patients has also been disproportionately represented patients with malignancy treated at 6 Australian tertiary cen- among those with severe infections from infl uenza A pan- ters during winter 2009. (cdc.gov)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. (uchicago.edu)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. (uchicago.edu)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A retrospective analysis from The Australasian Bone Marrow Transplant Recipient Registry. (cdc.gov)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • some patients will need ongoing maintenance therapy depending on how much consolidation treatment they have received, as well as if they had a stem cell transplant. (oncolink.org)
Myelodysplastic Syndromes6
Refractory11
  • February 11, 2021 - Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia. (onclive.com)
  • In the study, patients with active, relapsed, refractory AML are randomized 1:1 to receive either apamistamab conditioning therapy and allogeneic HCT or conventional care. (onclive.com)
  • This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). (survivornet.com)
  • I. Examine the anti-tumor activity and safety of administering patient-specific donor-derived (allogeneic) CD33-CAR T cells following lymphodepletion in research participants with CD33+ recurrent/refractory (r/r) acute myeloid leukemia ( AML ). (survivornet.com)
  • Refractory AML is defined as patients that have not achieved a first CR after induction chemotherapy. (survivornet.com)
  • Therapeutic Candidate or Device Cryopreserved autologous TRAC locus 1XX BCMA-CAR T cells Indication Relapsed and Refractory Multiple Myeloma Therapeutic Mechanism Engineered T cells target and kill BCMA+ Myeloma cells Unmet Medical Need No durable treatments are available for RRMM and only ~30% of patients can access current BCMA CAR therapies. (ca.gov)
  • Indication The target indication is relapsed/refractory secondary acute myeloid leukemia (sAML), or int-2 or high-risk myelofibrosis (MF). (ca.gov)
  • Compared with the poor outcomes of patients who received allo-HCT during refractory (active) disease, the outcomes of patients who received more than one induction cycle to achieve complete remission is somewhat better but remains unsatisfactory. (ascopost.com)
  • FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer, Inc.), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (org.in)
  • FDA granted accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. (org.in)
  • FDA granted accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. (org.in)
Bone30
  • Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, and anemia with nucleated and teardrop-shaped red blood cells. (msdmanuals.com)
  • Diagnosis requires bone marrow aspirate and biopsy and exclusion of other conditions that can cause myelofibrosis (secondary myelofibrosis). (msdmanuals.com)
  • Myelofibrosis is a reactive, reversible increase in bone marrow collagen often with extramedullary hematopoiesis (primarily in the spleen). (msdmanuals.com)
  • Primary myelofibrosis results from neoplastic transformation of a multipotent bone marrow stem cell. (msdmanuals.com)
  • These primary myelofibrosis progeny cells stimulate bone marrow fibroblasts (which are not part of the neoplastic transformation) to secrete excessive collagen. (msdmanuals.com)
  • It involves the abnormal development and function of bone marrow cells that produce blood cells and leads to the formation of scar tissue in the bone marrow. (radiationoncologyassociates.co)
  • When the bone marrow becomes scarred it can't make enough blood cells and this can cause anemia, enlargement of the spleen and liver, fatigue, and other problems. (radiationoncologyassociates.co)
  • When myelofibrosis develops on its own (and not as the result of another bone marrow disease), it's called primary myelofibrosis . (radiationoncologyassociates.co)
  • Once a diagnosis is suspected additional tests or procedures that may be used to diagnose primary myelofibrosis include blood tests and a bone marrow examination 2 . (radiationoncologyassociates.co)
  • Bone marrow examination typically reveals an increase in abnormal megakaryocytes (platelet-forming cells) and other abnormalities that are characteristic of myelofibrosis. (radiationoncologyassociates.co)
  • Bone marrow aspiration and biopsy with cytogenetic studies are required in most, but not all, patients. (medscape.com)
  • In the case of myelofibrosis, bone marrow fibrosis is demonstrated on the reticulin stain. (medscape.com)
  • Bone marrow fibrosis is also detected in the spent phase of chronic myelogenous leukemia and polycythemia vera. (medscape.com)
  • MPNs can sometimes transform to leukemia or to myelofibrosis, an MPN that is characterized by excessive scar-type tissue in the bone marrow. (ucsfhealth.org)
  • Therapeutic Mechanism Bone marrow transplants are standard of care for AIDS-lymphoma patients providing a cure for the patient's lymphoma. (ca.gov)
  • Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. (stembook.org)
  • Criteria for diagnosis of MDS consist of anemia, thrombocytopenia, or neutropenia that persist for six months or longer, dysplasia greater than 10% in at least one bone marrow cell lineage, and MDS associated clonal cytogenetic abnormalities or molecular markers. (standardofcare.com)
  • Conditions associated with bone marrow failure such as aplastic anemia with hypocellular marrow, typical bone marrow findings of MDS are a hypercellular marrow for a persons age, dysplasia in 1 to 3 lineages manifested by pseudo Pelger-Huet nuclei, hypogranular neutrophils, micro megakaryocytes, and/or ringed sideroblasts, glass Siri glass, and increased myeloblasts in a subset of patients. (standardofcare.com)
  • In patients with unexplained anemia, thrombocytopenia, or neutropenia without dysplasia in the bone marrow but with abnormal chromosome activity in 5, 7 or 13 the diagnosis is consistent with MDS and occurs in less than 10% of patients with MDS. (standardofcare.com)
  • When the bone marrow hematopoietic cells are mostly clonally derived cells, the disease is clinically manifested as cytopenia and morphologic dysplasia. (standardofcare.com)
  • The number of related HCTs has remained stable, while the use of peripheral blood stem cells (PBSCs) has now largely replaced that of bone marrow (BM). (apbmt.org)
  • in turn, each of these categories is classified as either acute or chronic, depending on the proportion of morphologically and immunophenotypically immature precursors (blasts) in the bone marrow or peripheral blood. (medilib.ir)
  • bone marrow or peripheral blood blasts of 20 percent or more) and the chronic myeloid disorders (bone marrow or peripheral blood blasts less than 20 percent). (medilib.ir)
  • The paradox of proliferative bone marrow together with peripheral blood cytopenias in MDS may be explained by increased intramedullary myeloid precursor cell apoptosis [ 6 ]. (medilib.ir)
  • most of the neutrophils in the body are contained in the bone marrow, either as mitotically active (one third) or postmitotic mature cells (two thirds). (medscape.com)
  • Three-dimensional reconstruction of bone marrow whole-mount tissue (1.2 mm × 1.2 mm × 100 μm) from a patient with severe aplastic anemia, showing most of the hematopoietic space occupied by adipocytes (green), with visualization also of the vascular network (CD34, red) and residual hematopoietic cell nuclei (DAPI, blue). (ashpublications.org)
  • Ma DD , 2007 , 'Expression of Neurofilament Proteins in Adult Bone Marrow Mesenchymal Stem Cells and Embryonic Stem Cells and Their Clinical Potential' , in Davenport LP (ed. (edu.au)
  • A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets. (jax.org)
  • Extramedullary hematopoiesis (EMH) is likely the result of abnormal trafficking of hematopoietic stem cells (HSC) from the bone marrow to organs such as the spleen, liver, and lung, causing organomegaly and sometimes organ dysfunction. (cancernetwork.com)
  • Remission is when there are less than 5% blast cells in the bone marrow. (oncolink.org)
Polycythemia2
Relapse3
  • Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. (mdanderson.org)
  • Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. (uchicago.edu)
20232
  • Short Hills, New Jersey--(Newsfile Corp. - June 9, 2023) - Humanigen, Inc. (Nasdaq: HGEN) today extended previously reported results by presenting additional, statistically significant hematologic improvements and reductions in inflammatory markers from lenzilumab, its investigational drug, in a Phase 2/3 trial of treatment-naïve participants with chronic myelomonocytic leukemia and RAS -pathway mutations. (stocktitan.net)
  • The presentation, entitled "Lenzilumab and Azacitidine Improve Hematologic Alterations of Chronic Myelomonocytic Leukemia in the PREACH-M Trial," highlighted new data in poster format (P737) at 6:00 pm CEST on June 9, 2023, during the 2023 European Hematology Association congress. (stocktitan.net)
Mutations18
  • Mutations of the Janus kinase 2 ( JAK2 ) gene are present in a high proportion of cases of primary myelofibrosis. (msdmanuals.com)
  • Mutations of the thrombopoietin receptor gene ( MPL ) or the calreticulin ( CALR ) gene also may be the cause of primary myelofibrosis. (msdmanuals.com)
  • However, there are rare cases of primary myelofibrosis in which none of these three mutations are present (triple negative primary myelofibrosis). (msdmanuals.com)
  • Some of these patients have other uncommon MPL mutations, which can only be detected by next generation sequencing. (msdmanuals.com)
  • According to Baohui Han, MD, PhD, the confirmed objective response rate was 78.6% for treatment-naïve patients with non-small cell lung cancer with EGFR Exon20 insertion mutations treated with furmonertinib 240 mg daily in the FAVOUR trial. (targetedonc.com)
  • In MPN, mutations cause the affected stem cells to produce an abnormal number of these cells. (ucsfhealth.org)
  • Less common MPNs, which are not associated with the driver mutations, include chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia , and myeloproliferative neoplasm , unclassifiable. (amboss.com)
  • The mutation occurs in hematopoetic stem cells capable of self renewal and additional mutations are associated with clonal progression may occur in progenitor cells conferring a self renewal capability. (standardofcare.com)
  • Adverse mutations are present in approximately 20% of patients with very low risk MDS with a median survival nearly one third shorter than that have low-risk patients without these mutations. (standardofcare.com)
  • For patients with low and intermediate IPSS risk, mean overall survival was approximately 50% shorter compared with those without mutations. (standardofcare.com)
  • Patients with the greater number of somatic mutations have inferior overall survival. (standardofcare.com)
  • Somatic mutation is not a static process in myelodysplastic syndrome and additional mutations will accumulate leading to more profound phenotypic worsening cytopenias, and approximately 30% of patients will eventually experience progression to secondary AML. (standardofcare.com)
  • Controls were patients with AML who had a history of MDS or CMML and NPM1 mutations detected (n=31). (bloodcancerstoday.com)
  • Other notable findings were that concurrent baseline DNMT3A mutations tended to be associated with inferior outcomes, and patients who underwent transplantation had better outcomes. (bloodcancerstoday.com)
  • Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm]. (cdc.gov)
  • Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. (cdc.gov)
  • Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia. (mitteldeutsches-krebszentrum.de)
  • In the presence of RAS -pathway mutations, GM-CSF contributes to the hyperproliferation of myelocytes in myelodysplastic leukemias such as CMML, juvenile myelomonocytic leukemia (JMML), and acute myeloid leukemia (AML). (stocktitan.net)
Malignancies5
  • Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma. (targetedonc.com)
  • Determine the feasibility and efficacy of a reduced-intensity conditioning regimen comprising alemtuzumab, fludarabine, melphalan, and thiotepa followed by allogeneic peripheral blood stem cell transplantation (PBSCT) in patients with hematologic malignancies. (knowcancer.com)
  • CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES - The hematopoietic pluripotent stem cell is capable of both self-renewal and stepwise differentiation into either the lymphoid or myeloid lineage (which appears to be determined stochastically) [ 1 ]. (medilib.ir)
  • Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. (uchicago.edu)
  • SummaryChimeric antigen receptor T cells (CAR-T cells) are a novel form of cellular immunotherapy for patients with hematologic and oncologic malignancies. (deepdyve.com)
Multiple myeloma4
Survival12
  • Patients with low-risk primary myelofibrosis have a median survival of more than 15-years, whereas median survival in the high-risk patients is less than two years 4 . (radiationoncologyassociates.co)
  • I. Assess activity in the form of CAR T cell expansion and persistence, to assess impact on hematopoiesis, 6-month progression free survival (PFS 6mo) rate, duration of response, and 1-year overall survival (OS) rate. (survivornet.com)
  • Results showed that adding quizartinib to standard chemotherapy with or without allogeneic hematopoietic stem cell transplantation, followed by continuation monotherapy for up to 3 years, resulted in improved overall survival. (medscape.com)
  • After completion of study treatment, patients are followed weekly for 100 days post-transplantation and then periodically for survival. (knowcancer.com)
  • He has published significantly on this topic including recently in highly regarded journals including Leukemia and Haematologica and these work form the foundation of the clinical trials that he is bringing to patients in order to improve their quality of life and survival. (moffitt.org)
  • As an example, Dr. Sallman has focused research and clinical trial efforts on patients who have TP53 mutation (often associated with complex genes/cytogenetics) given their high risk of transformation to acute leukemia and poor survival. (moffitt.org)
  • Therapeutic Mechanism Destruction of host tumor stem cells by adaptive humoral cellular immunity will eradicate the origin of melanoma which will extend patient survival. (ca.gov)
  • Identification by random forest method of HLA class I amino acid substitutions associated with lower survival at day 100 in unrelated donor hematopoietic cell transplantation. (uchicago.edu)
  • Patients with resistant or relapsed (r/r) DLBCL have a poor prognosis with a median overall survival of 6,3 months and low complete response rates (CR 7%) to salvage chemoimmunotherapy. (deepdyve.com)
  • Incidence, Survival, and Risk Factors for Adults with Acute Myeloid Leukemia Not Otherwise Specified and Acute Myeloid Leukemia with Recurrent Genetic Abnormalities: Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database, 2001-2013. (cdc.gov)
  • Additionally, ruxolitinib is the only agent that has demonstrated a survival benefit in patients with MF. (cancernetwork.com)
  • Current treatment options for CMML patients are limited to blood transfusions, hydroxyurea, and supportive care alongside the current standard of care, which includes hypomethylating agents such as azacitidine and decitabine, which have limited response rates of 7% to 18% 1, 2, 3 with no proven increase in overall survival. (stocktitan.net)
Neoplasm3
  • Myelofibrosis is a type of blood cancer known as a myeloproliferative neoplasm that is chronic and progressive in nature. (radiationoncologyassociates.co)
  • Myelofibrosis (MF) is a hematopoietic stem cell malignancy classified as a myeloproliferative neoplasm (MPN). (cancernetwork.com)
  • Blastic plasmacytoid dendritic cell neoplasm. (oncolink.org)
Hematology1
  • The researchers, who presented their findings at the 64th American Society of Hematology Annual Meeting & Exposition, said the results support the World Health Organization's proposal to reclassify these types of MNs into acute myeloid leukemia (AML), regardless of blast counts, so that these patients can benefit from more intensive treatments. (bloodcancerstoday.com)
Lymphoma7
  • The diffuse large B-cell lymphoma treatment landscape is evolving with Pola-R-CHP and CAR T-cell therapy moving into the frontline setting. (targetedonc.com)
  • Data points to the loss of predictive value of an interim PET2 scan for patients with Hodgkin lymphoma when treated with a regimen containing brentuximab vedotin. (targetedonc.com)
  • Guidance from the FDA has provided a clear pathway and requested no additional efficacy or safety trials for the resubmission of the biologics license application for denileukin diftitox in cutaneous T-cell lymphoma. (targetedonc.com)
  • Severe veno-occlusive disease after autologous peripheral blood stem cell transplantation for high-grade non-Hodgkin lymphoma: report of a successfully managed case and a literature review of veno-occlusive disease. (unicatt.it)
  • Indication HIV in AIDS-lymphoma patients. (ca.gov)
  • FDA approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater. (org.in)
  • SummaryDiffuse large B‑cell lymphoma (DLBCL) comprises 30-40% of non-Hodgkin's lymphoma. (deepdyve.com)
HSCT6
Intermediate or high-risk myelofibrosis1
  • FDA has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythaemia vera and post-essential thrombocythaemia), in adults with anaemia. (org.in)
Transplants2
  • Blood-forming stem cell transplants. (mayoclinic.org)
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
Myelogenous Leukemia8
  • Role of signal transduction inhibition in treatment of acute myelogenous leukemia/myelodysplasia. (rochester.edu)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • Hematopoietic stem cell transplantation can be considered in young patients with chronic myelogenous leukemia in chronic phase if a human leukocyte antigen (HLA)-matched donor is available. (medscape.com)
  • Patients with chronic myelogenous leukemia and myelofibrosis often feel tired and report pain or fullness in their belly from an enlarged spleen. (ucsfhealth.org)
  • The treatment of choice for chronic myelogenous leukemia is a new anti-leukemia medication, called Gleevec. (ucsfhealth.org)
  • Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. (uchicago.edu)
  • Chronic myelogenous leukemia (CML), also known as chronic myeloid leukemia, is a myeloproliferative disorder characterized by increased proliferation of the granulocytic cell line without the loss of their capacity to differentiate. (medscape.com)
  • Acute myelogenous leukemia (AML) is a blood cancer that affects white blood cells, red blood cells, and/or platelets. (oncolink.org)
Cancers4
  • Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. (survivornet.com)
  • Therapeutic Candidate or Device Rebecsinib is a novel small molecule inhibitor of ADAR1 splicing that selectively eradicates therapy-resistant cancer stem cells in blood cancers. (ca.gov)
  • Another important class of tumor suppressor genes involved in cell cycle control and in the generation of human cancers is the cyclin-dependent kinase (CDK) inhibitors. (medscape.com)
  • See Chronic Leukemias: 4 Cancers to Differentiate , a Critical Images slideshow, to help detect chronic leukemias and determine the specific type present. (medscape.com)
Hematologic4
  • Myeloproliferative diseases are a heterogeneous group of disorders characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. (medscape.com)
  • 50% of patients who died had an underlying hematologic pital, Sydney, New South Wales, Australia (B. George, D.E. Dw- malignancy ( 15 ). (cdc.gov)
  • Concurrent anemia, thrombocytopenia, and/or an abnormal result on a peripheral blood smear from a patient with neutropenia suggest an underlying hematologic disorder. (medscape.com)
  • Lenzilumab, a granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibody, prevents GM-CSF from binding to receptors on hematologic progenitor cells. (stocktitan.net)
Secondary acute leukemia1
  • They are also at risk of developing secondary acute leukemia from their underlying disorder, as well as from their treatment. (medscape.com)
Promyelocytic leukemia1
  • We describe the first case of a genetically diagnosed acute promyelocytic leukemia presenting with nephrotic range proteinuria that resolved with induction therapy with ATRA and ATO and performed a comprehensive review. (karger.com)
Hematopoietic cells1
  • I. Change from baseline in numbers of CD33+ blood cells, CD33 expression on leukemia cells and hematopoietic cells. (survivornet.com)
Diagnosis4
  • The following is a general overview of the diagnosis and treatment of myelofibrosis. (radiationoncologyassociates.co)
  • See "Clinical manifestations and diagnosis of primary myelofibrosis" . (medilib.ir)
  • See "Clinical manifestations and diagnosis of chronic myeloid leukemia" . (medilib.ir)
  • Other laboratory studies that may aid in diagnosis include the red cell count, mean corpuscular volume, and red cell distribution width (RDW), particularly when the hematocrit or hemoglobin levels are less than 60% or 20 g/dL, respectively. (basicmedicalkey.com)
Chemotherapy6
  • Rapidly progressive, chemotherapy-incurable acute leukemia Overview of Leukemia develops in about 30% of patients. (msdmanuals.com)
  • Considering these points, we designed a trial to examine ruxolitinib in combination with intensive cytotoxic chemotherapy for patients with post-MPN AML in good physical condition. (bloodresearch.or.kr)
  • Adult (age ≥18 yr) patients with cytologically confirmed AML following MPN were eligible if they had adequate physical condition and organ function and could tolerate cytotoxic induction chemotherapy. (bloodresearch.or.kr)
  • FDA approved quizartinib (Vanflyta, Daiichi Sankyo, Inc.) with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (org.in)
  • Although the incidence of acute nonlymphocytic leukemia is increased in PV, the incidence of acute leukemia in patients not exposed to chemotherapy or radiation therapy is low. (basicmedicalkey.com)
  • Interestingly, chemotherapy, including hydroxyurea, has been associated with acute leukemia in JAK2 V617F-negative stem cells in some PV patients. (basicmedicalkey.com)
Adults7
  • Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. (stembook.org)
  • Since its establishment in 2010, the Adult AML Working Group within the JSHCT has been using this registry data to complete several studies focusing on various aspects of HCT in adults with AML, with particular attention paid to patient-, disease-, and transplantation-related factors. (apbmt.org)
  • Figure 1 shows the trend in the annual number of allogeneic and autologous HCTs in adults with AML reported in the Japanese transplantation registry. (apbmt.org)
  • 1,000 adults with AML currently undergoing allogeneic HCT per year. (apbmt.org)
  • Here you can find a continually updated listing of Memorial Sloan Kettering's current clinical trials for adults with leukemia. (mskcc.org)
  • Naturally, more fit younger patients were able to receive more intensive conditioning regimens than less fit older adults. (ascopost.com)
  • It accounts for 20% of all leukemias affecting adults. (medscape.com)
Platelets3
  • The peripheral smear below shows leukoerythroblastosis and giant platelets in a patient with myelofibrosis. (medscape.com)
  • These stem cells normally give rise to mature cells found in the blood, such as red blood cells, which carry oxygen, white blood cells, which fight infection, and platelets, which facilitate blood clotting. (ucsfhealth.org)
  • Many of the clinical complications of PV relate directly to the increase in blood viscosity associated with red cell mass elevation and indirectly to the increased turnover of red cells, leukocytes, and platelets with the attendant increase in uric acid and cytokine production. (basicmedicalkey.com)
Proliferation3
  • Quizartinib and its active metabolite (AC886) inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting downstream FLT3 receptor signaling and blocking FLT3-ITD-dependent cell proliferation. (medscape.com)
  • There is clonal proliferation of malignant hematopoietic stem cells, dysregulated cellular differentiation, and compromised tissue function. (standardofcare.com)
  • Inactivation of tumor suppressor genes, whose products normally provide negative control of cell proliferation, contributes to malignant transformation in various cell types. (medscape.com)
Splenomegaly3
  • While not a curative option, ruxolitinib offers great palliative potential and results in significant reduction in splenomegaly and improvement in constitutional symptoms in the majority of treated patients, thus improving their quality of life and performance status. (cancernetwork.com)
  • Patients with massive splenomegaly are particularly prone to thrombotic events because the associated increase in plasma volume masks the true extent of the red cell mass elevation measured by the hematocrit or hemoglobin level. (basicmedicalkey.com)
  • A "normal" hematocrit or hemoglobin level in a PV patient with massive splenomegaly should be considered indicative of an elevated red cell mass until proven otherwise. (basicmedicalkey.com)
Chronic myeloid disorders2
  • The chronic myeloid disorders - The chronic myeloid disorders encompass several clinicopathologic entities. (medilib.ir)
  • Clonal studies in the chronic myeloid disorders - Genetic and enzyme studies based upon X-chromosome inactivation patterns have revealed a multipotent progenitor cell origin for the neoplastic clone in both MDS [ 8 ] and MPN [ 9 ]. (medilib.ir)
Mutation6
  • Roughly half of the people with primary myelofibrosis will test positive for a mutation in the Janus kinase 2 (JAK2) gene and the majority of individuals will have overactive JAK signaling even if the don't have a JAK mutation. (radiationoncologyassociates.co)
  • Most patients with myelodysplastic syndrome have greater than one mutation and a unique pattern of mutation with marked heterogeneity. (standardofcare.com)
  • The paradox is that the mutation provides advantage at the stem cell level and progenitor cells, with a disadvantage at the level of hematopoietic precursors. (standardofcare.com)
  • Ultimately, 64% of patients with MN and NPM1 mutation transformed to AML in a median 21.1 months. (bloodcancerstoday.com)
  • Germline mutation of one TP53 allele is found in patients with Li-Fraumeni syndrome who generally inherit a mutated TP53 gene from an affected parent. (medscape.com)
  • The discovery of an activating point mutation in the Janus kinase 2 gene ( JAK2 V617F) in a significant portion of patients with MPNs led to improved understanding of the pathobiology of these disorders and prompted rapid development of JAK inhibitors. (cancernetwork.com)
Thrombocytopenia1
Hematopoiesis6
  • In primary myelofibrosis, nucleated red blood cells (normoblasts) and myelocytes are released into the circulation (leukoerythroblastosis) when there is extramedullary hematopoiesis (ie, non-marrow organs have taken over blood cell production because of the fibrosed marrow). (msdmanuals.com)
  • Clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and peripheral cytopenias. (standardofcare.com)
  • Thus, during normal hematopoiesis, there exists a cellular hierarchy headed by a stable population of pluripotent stem cells that generate lineage-specific progenitors, which differentiate into the various types of mature blood cells [ 2 ]. (medilib.ir)
  • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. (harvard.edu)
  • Myelofibrosis appears to be part of the natural history of the disease but is a reactive, reversible process that does not itself impede hematopoiesis and by itself has no prognostic significance. (basicmedicalkey.com)
  • In approximately 15% of patients, however, myelofibrosis is accompanied by significant extramedullary hematopoiesis, hepatosplenomegaly, and transfusion-dependent anemia, which are manifestations of stem cell failure. (basicmedicalkey.com)
Therapy for patients with myelofibrosis2
  • With multiple JAK inhibitors now available to choose from, patient- and disease-specific factors are vital in determining the most appropriate therapy for patients with myelofibrosis. (targetedonc.com)
  • In this article, we provide updated data on ruxolitinib therapy for patients with myelofibrosis and offer expert opinion on the appropriate use of this agent in the community practice. (cancernetwork.com)
Incidence2
Renal cell carc2
  • Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. (uchicago.edu)
  • Gühne F , Seifert P , Theis B , Steinert M , Freesmeyer M , Drescher R . PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings. (mitteldeutsches-krebszentrum.de)
Progenitor3
  • Therapeutic Candidate or Device The therapeutic product candidate is autologous CD34+ hematopoietic stem/progenitor cells (HSPC) transduced with the G1XCGD lentiviral vector. (ca.gov)
  • The impact of pre-apheresis Health Related Quality of Life on peripheral blood progenitor cell yield and donor's health and outcome: Secondary analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. (stembook.org)
  • The clonal process may develop at different progenitor cell levels in individual patients, and the clonal progenitor cell may or may not involve T and B lymphocytes [ 10 ]. (medilib.ir)
Clinical Trials3
  • Interested patients may have the option to participate in clinical trials of potential new therapies. (ucsfhealth.org)
  • Safety and robust efficacy had previously been demonstrated with the agent in 271 patients treated in 9 different phase 1 and 2 clinical trials. (onclive.com)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
Peripheral blood stem1
MPNs3
  • We analyzed the clinical impact of JAK2V617F allele burden in a relatively large series of patients with Ph-negative MPNs and long-term follow-up. (bvsalud.org)
  • Generally, MPNs are associated with an overproduction of some of the mature blood cell types. (ucsfhealth.org)
  • MPNs may also be seen incidentally when routine blood work shows abnormal cell counts on CBC . (amboss.com)
Tyrosine kinase inh1
  • However, results from BCR-ABL1 -positive AML suggest that tyrosine kinase inhibitors alone are insufficient to control acute-phase leukemia. (bloodresearch.or.kr)
Donor9
  • Patients are eligible for enrollment if they have marrow blast count ≥ 5% or the presence of peripheral blasts, age ≥ 55 years, a Karnofsky score ≥ 70, and related/unrelated donor matching at human leukocyte antigen (HLA)-A, HLA-B, HLA-C, and DRB-1. (onclive.com)
  • Determine the safety of LMB-2 immunotoxin-treated, selectively-depleted donor T cells, administered after allogeneic PBSCT, in these patients. (knowcancer.com)
  • OUTLINE: This is a dose-escalation study of LMB-2 immunotoxin-treated, selectively-depleted donor T cells. (knowcancer.com)
  • Patients' PBMCs are irradiated and mixed with donor PBMCs. (knowcancer.com)
  • LMB-2 immunotoxin is added to the PBMCs in order to selectively deplete T cells from the donor PBMCs. (knowcancer.com)
  • LMB-2 immunotoxin-treated, selectively-depleted donor T cells: Patients receive LMB-2 immunotoxin-treated, selectively-depleted donor T cells IV over 30-60 minutes on approximately day 28. (knowcancer.com)
  • Cohorts of 3-6 patients receive escalating dose of LMB-2 immunotoxin-treated, selectively-depleted donor T cells until the maximum tolerated dose (MTD) is determined. (knowcancer.com)
  • Overview and choice of donor of hematopoietic stem cell transplantation. (mayoclinic.org)
  • Various factors including age, sex, performance status (PS), disease status, cytogenetic risk, donor type, graft source, sex mismatch between the donor and the recipient, and year of transplantation were all shown to impact OS 2 . (apbmt.org)
Megakaryoblastic2
  • Malignant myelofibrosis (sometimes called acute myelofibrosis), is a rare variant of myelofibrosis characterized by pancytopenia, myeloblastosis, and marrow fibrosis that has a more rapidly progressive downhill course and is generally due to a type of acute leukemia called acute megakaryoblastic leukemia. (msdmanuals.com)
  • Acute megakaryoblastic leukemia. (oncolink.org)
JAK21
Primary6
  • People with primary myelofibrosis often have low red blood cell counts (anemia) in addition to other blood cell abnormalities. (radiationoncologyassociates.co)
  • Commonly used scoring systems for primary myelofibrosis consider these and assign a patient to one of four risk groups: low risk, intermediate-1 risk, intermediate-2 risk, or high-risk. (radiationoncologyassociates.co)
  • 01). Treatment-related mortality was similar for patients with primary induction failure vs those in first complete remission after myeloablative or reduced-intensity conditioning allo-HCT (Table 1). (ascopost.com)
  • Phase II study of ruxolitinib given pre-, peri- and post-allo-HCT for patients with primary or secondary myelofibrosis (ClinicalTrials.gov identifier NCT03427866). (ascopost.com)
  • The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance. (cdc.gov)
  • GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. (cdc.gov)
Severe2
  • Patients with MPN may have moderate or severe anemia, a condition where there are not enough red blood cells to carry oxygen. (ucsfhealth.org)
  • Indication The target indication is for the transplantation of patients with severe X-linked Chronic Granulomatous Disease (XCGD) lacking matched donors. (ca.gov)
Hematopoetic stem cell1
  • The MDS cell of origin is a hematopoetic stem cell that proliferates and escapes apoptosis. (standardofcare.com)
Blast phase1
  • Dasatinib (Sprycel): Indicated for the treatment of adult patients with chronic myeloid leukemia in chronic, accelerated, or myeloid or lymphoid blast phase who are resistant or intolerant to prior therapy including imatinib. (medscape.com)